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pharmacokineticsAbstract The purpose of this study was to use the stochastic simulation and estimation method to
evaluate the effects of sample size and the number of samples per individual on the model develop-
ment and evaluation. The pharmacokinetic parameters and inter- and intra-individual variation
were obtained from a population pharmacokinetic model of clinical trials of amlodipine. Stochastic
simulation and estimation were performed to evaluate the efﬁciencies of different sparse sampling
scenarios to estimate the compartment model. Simulated data were generated a thousand times and
three candidate models were used to ﬁt the 1000 data sets. Fifty-ﬁve kinds of sparse sampling sce-
narios were investigated and compared. The results showed that, 60 samples with three points and
20 samples with ﬁve points are recommended, and the quantitative methodology of stochastic sim-
ulation and estimation is valuable for efﬁciently estimating the compartment model and can be used
for other similar model development and evaluation approaches.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The standard pharmacokinetic approaches of the compart-
ment model estimation rely heavily on rich blood sampling
data. However, it is often inconvenient or impossible for phy-
sicians and pharmacists to perform a rich blood sampling in
some occasions since the number of blood sampling is limited
in some special populations, such as children or older people.
The population pharmacokinetic approaches are often used to
solve this problem, which can use only a fewer number of drug
concentration samples (sparse data) to estimate the pharmaco-
kinetic parameters of the compartment model. However,
sparse sampling designs often fail to support models derived
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1996; Flynn et al., 2006). Therefore, it is very important to
analyze and evaluate the important inﬂuential factors of model
estimation (Ette et al., 1995; Hooker et al., 2007).
Sample location in a population pharmacokinetic study is
an important factor. Ette et al. investigated a 2-time-point
design with one-compartment IV bolus model and extended
to 3- and 4-time-point designs via simulation (Roy and Ette,
2005; Ette et al., 1995). With the ﬁrst time point sampled as
early as possible, they found that the second sample point be-
tween 1.4 and 3.0 times the half-life of the drug produced bet-
ter estimation and the exact location of the third and fourth
time point for the three and four time point designs was not
critical to the efﬁciency of overall efﬁciency of parameter esti-
mation, although some parameters were sensitive to the loca-
tion of these sample times. The quality of pharmacokinetic
modeling and parameters’ estimation of the population meth-
od usually depends heavily upon sample size and the number
of sampling points. Al-Banna et al. found that the accuracy
and precision of random effect parameter estimates improved
dramatically when the number of sampling points increased
(Al-Banna et al., 1990). For a same data set, sometimes the re-
sults show that the two-compartment model is the best model
to describe the data if modeling on rich data. But sometimes, if
using fewer sampling points per subject, the one-compartment
model may also be the best model to ﬁt the data. This might be
because sampling points are not enough to distinguish the dis-
tribution and elimination phases (Hooker et al., 2007).
Amlodipine is a second-generation calcium channel antag-
onist. Some previous studies have reported that the pharmaco-
kinetics of amlodipine conforms to the one-compartment
model (Flynn et al., 2006) or one-compartment model with
absorption lag time (Rohatagi et al., 2008). There are also
some other pharmacokinetic studies which reported that it
conforms to the two-compartment model (Faulkner et al.,
1986; Cheng et al., 1996). A Limited Sampling strategy
(LSS) model of amlodipine was successfully developed and val-
idated to estimate the area under the concentration–time curve
(AUC) (Suarez-Kurtz et al., 1999). In the present study, we
mainly focus on the effects of the number of sampling points
and sample size on the compartment model evaluation in var-
ious random sparse sampling designs. Population pharmacoki-
netic models of amlodipine were developed using data
collected from three bioequivalence clinical trials in healthy
Chinese volunteers with a total of 120 samples. A two-com-
partment model with lag time obtained from real clinical trial
data of amlodipine was used as an example. The efﬁciencies of
compartment model estimation in different sparse sampling
scenarios were investigated and compared.2. Materials and methods
2.1. Data
The data used for modeling and simulation were obtained
from three randomized, two-period crossover bioequivalence
clinical trials of amlodipine, in which the treatment phases
were separated by a 14-day washout interval. Sixty healthy
male volunteers ranging from 19 to 25 years of age (mean
21.7 years) and from 51 to 87 kg in weight (mean 62.8 kg) were
enrolled in the study. The clinical protocol was approved bythe ethics committee and all participants provided written in-
formed consent.
The volunteers received an amlodipine 5 mg tablet with
200 ml water at 7:30 am after an overnight (>10 h) fast. Blood
samples (3 ml) were collected before the initiation of the study
and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h after
the administration of amlodipine. Amlodipine concentrations
were analyzed by liquid chromatography tandem mass spec-
trometry. The visible detection of the method was in the range
of 0.2–32.0 ng/ml, and the lower limit of quantiﬁcation for
amlodipine was 0.2 ng/ml.
2.2. Software
Nonlinear mixed-effect methodology (NONMEM software,
version 7.1.0, Icon Development Solutions, Ellicott, MD,
USA) was used to ﬁt the population model. The Perl speak
to NONMEM toolkit (PsN version 4.2.3, Uppsala University,
Sweden) was used in conjunction with NONMEM. Data
manipulation and graph drawing were accomplished by R
2.13, Xpose (version 4.3.0, Uppsala University, Sweden) and
Lattice (Sarkar, 2008).
2.3. Candidate models
Compartment model estimation proceeded from a one-com-
partment model with ﬁrst-order input and ﬁrst-order elimina-
tion (1-cp model). The pharmacokinetic parameters were
estimated. Subsequently, one-compartment with absorption
lag time model (1-cp-lag model), two-compartment model
(2-cp model) and two-compartment with absorption lag time
(2-cp-lag model) were evaluated. The approximate maximum
likelihood technique known as the ﬁrst-order conditional esti-
mation (FOCE) method was used to estimate the model
parameters. The likelihood ratio (LR) test and graphical tools
were used as the criteria of compartment model selection to as-
sess whether a model is good enough to describe the data. The
LR test is based on the difference of objective function value
(OFV) of two compared models. The difference of OFV
approximately follows a v2 distribution, and the degree of free-
dom is equal to the different numbers of parameters between
the two compared models. Difference in OFV of 3.84, 5.99
and 7.81 corresponds to P< 0.05 for 1, 2 and 3 degrees of
freedom, respectively.
2.4. Statistic model
Random components are assumed to be derived from an expo-
nential distribution. An individual parameter (Pj) is distributed
according to
Pj ¼ TVP egj ð1Þ
where, Pj is the parameter of subject i, TVP is the typical
parameter value and gj is the random effect which is normally
distributed around zero with variance x2 reﬂecting the inter-
individual variability.
Three error models tested in this study, additive (2), pro-
portional (3) and mixed (4) error models, were postulated as:
Ci;obs ¼ Ci;pred þ i ð2Þ
Ci;obs ¼ Ci;pred  i ð3Þ
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where Ci,obs and Ci,pred denote the observed and predicted data
of the ith subject, respectively. ei is assumed to follow a normal
distribution with mean equal to 0 and variance r2 reﬂecting the
intra-individual variability.
2.5. Visual predict check
Visual predictive checks (VPC) were used to graphically assess
the appropriateness of the compartment model since the ability
of the model to simulate data similar to the original data was
an important factor. The principle is to graphically assess
whether simulations from the candidate models are able to
reproduce the central trend and the variability in the observed
data when plotted versus time. One thousand simulated data-
sets were generated using the same design as the original data.
Each simulated dataset was graphically compared with the ori-
ginal data. The VPC graphs consist of a shadow area repre-
senting the 95% conﬁdence interval for the median and the
25th and 975th percentiles of the 1000 simulated datasets from
the original model. The VPC graphs also include the original
data and lines of median and the 95% conﬁdence interval.
Any miss-speciﬁcations were visualized by the difference in
lines and shadow area which represents the observed and sim-
ulated data, respectively. The VPC was performed by PsN
3.2.4 and the graphs were plotted by Xpose 4.3.
2.6. Model stability and diagnostic plots
One thousand bootstrap replicate datasets were produced from
the ﬁnal model and analyzed with NONMEM. This approach
was used to assess the stability of the results of the population
pharmacokinetic model development. The results of distribu-
tion of parameters were compared to the originally estimated
parameters. This is a valuable step to conﬁrm that the devel-
oped model is an appropriate model. The 95% conﬁdence
intervals (CI) of parameters were also obtained by the boot-
strap in percentile method.
The scatter plots of observed plasma concentrations versus
the population and individual predictions were shown as good-
ness-of-ﬁt plots for the ﬁnal model. The absolute value of the
individually weighted residuals versus individual predictions
and conditional weighted residual error (CWRES) versus time
were plotted (Hooker et al., 2007). The smooth nonparametric
regression line was used to show whether there is deviation
from the model.
2.7. Sparse sampling scenarios
Since the statistical power of choosing the right compartment
model might depend on the sample points and sample size, we
used the following ﬁve sparse sampling scenarios (2–6 points)
to detect the power. Two to six sample points were randomly
taken from each bracket listed below for every subject,
respectively.
(1). 2 points: (1, 2, 4, 6, 8, 12, 24), (36, 48, 72, 96, 120, 144).
(2). 3 points: (1, 2, 4, 6), (8, 12, 24, 36, 48), (72, 96, 120,144).
(3). 4 points:(1, 2, 4, 6), (8, 12, 24), (36, 48, 72), (96, 120, 144)
(4). 5 points:(1, 2),(4, 6, 8), (12, 24, 36), (48, 72), (96, 120,
144)(5). 6 points:(1, 2),(4, 6), (12, 24), (36, 48), (72, 96), (120, 144)
Since the sample size might be directly related to the efﬁ-
ciency of compartment estimation, we calculated the estima-
tion efﬁciencies for a large range of sample sizes, ie., from 20
to 120 with an interval equal to 10 for each number of sam-
pling points. That is, a total of 55 sparse sampling scenarios
were investigated.
2.8. Statistical power of choosing the right model
Stochastic simulation and estimation (SSE) were performed to
evaluate the efﬁciencies of the selected sparse designs to esti-
mate compartment model and parameters. Statistical power
(success rate) of the chosen right compartment model is
deﬁned as the type II error. It describes the probability of
rejecting the candidate model, given the 2-cp-lag model was
the right model. In this study, for each of the sparse designs,
1000 datasets were simulated with the ﬁnal 2-cp-lag time mod-
el. Subsequently, the population pharmacokinetic parameters
for each of the 1000 simulated datasets were estimated with
the same population 2-cp-lag model (the right model) as the
one used to simulate the datasets. 2-cp model, 1-cp-lag model
and 1-cp model were used to ﬁt these data, which means there
were 1000 times simulation and 4000 times ﬁtting for each sce-
nario. Parameter estimation was performed using the FOCE
method in NONMEM. The reference OFV value was obtained
when estimating parameters using the 2-cp-lag model for each
simulated dataset. The OFV values of the other three models
were compared with this reference. The criteria of choosing
the right model (2-cp-lag model) is that the OFV of 2-cp-lag
model should be lower 3.84, 5.99 and 7.81 (corresponding to
P= 0.05 for 1, 2 and 3 degrees of freedom) than 1cp, 1-cp-
lag and 2-cp model, respectively. If not detecting signiﬁcant
OFV difference to 1-cp, 1-cp-lag and 2-cp model in one data-
set, this case is deﬁned as reducing to 1-cp, 1-cp-lag and 2-cp
respectively. The success rates (power) of rejecting the three
candidate models and choosing the right model (2-cp-lag mod-
el) were summarized after 4000 times ﬁtting. The stochastic
simulation and estimation were as performed by SSE script
of PsN 3.2.4 and the graphs were plotted by Lattice.
3. Results
The modiﬁed box and whisker plots of plasma concentration
at zero time and 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and
144 h after the administration of amlodipine are shown in
Fig. 1..
Compartment model estimation started from a 1-cp model
with ﬁrst order input and ﬁrst order elimination, which was
parameterized in terms of CL/F, V, and Ka. 1-cp-lag model,
2-cp model and 2-cp-lag model were subsequently used. Resid-
ual error was modeled using an additive and proportional error
model. All the four models are successfully minimized. The re-
sults of OFV are displayed in Table 1. The addition of absorp-
tion lag (ALAG) time decreased the OFV signiﬁcantly by 181.4.
The OFV decreases to 21.5 when using the 2cp model with ﬁve
parameters. Although smaller than the effect of ALAG, it still
has a signiﬁcant effect. When ALAG was added to the 2cp
model, the goodness of ﬁt increased signiﬁcantly compared to
1-cp model (the OFV decreased 359.9). These results of the
OFV suggest that the 2-cp-lag model describes the data best.
Figure 1 Box plot of plasma concentrations at different times after the administration of 5 mg amlodipine. The median, ﬁrst and third
quartiles are used to construct the box and the outlier is represented by an empty circle.
Table 1 The object function value (OFV) of using NON-
MEM to ﬁt amlodipine population pharmacokinetics data of
120 health volunteers with 1-cp, 1-cp-lag, 2-cp and 2-cp-lag
model.
OFV DOFV P
1-cp 1367.5 0 -
1-cp-lag 1549.0 181.4 <0.001
2-cp 1570.4 202.9 <0.001
2-cp-lag 1727.5 359.9 <0.001
66 X.-h. Huang et al.Fig. 2 shows the visual predict checks for 1cp, 1cp_lag, 2cp
and 2cp_lag model. Obviously, 2-cp and 2cp-lag model demon-
strated a better ﬁt to high concentration data than the 1-cp and
1-cp-lag models. The median and lower percentiles shadow
areas are lower estimated the median lines and 2.5% percen-
tiles line at the tails of observed data. When ALAG is added,
the miss-speciﬁcations improved slightly. For 2-cp and 2-cp-
lag model, the miss-speciﬁcations of 2.5% percentiles are smal-
ler. But the median becomes worse in 2-cp model. The VPC of
ﬁnal 2-cp-lag model (d) shows a better agreement of simulated
datasets and the observation. This provides further evidence
that 2-cp-lag model is more suitable for this data.
Table 2 summarizes the ﬁnal parameter estimates and 95%
conﬁdence interval for the 2-cp-lag model, together with the
mean, median and 95% conﬁdence interval of 1000 bootstrap
samples. The mean and median from bootstrap resampling
even the 95% conﬁdence intervals coincide well with the NON-
MEM parameter estimates.
Diagnostic plots of population and individual prediction
versus observations are shown in Fig. 3 (a) and (b), respec-
tively. The data points line up nicely around the unit line.
The nonparametric smooth regression lines agree well with
the unit line. The absolute value of the individually weighted
residuals (iWRES) versus individual predictions and condi-
tional weighted residuals (CWRES) versus time are presented
in (c) and (d). The solid smooth nonparametric regression lines
in (c) and (d) indicate there no underlying trends from the
horizontal which indicates that the model has no misspeciﬁca-
tion of data.The results of successful ﬁtting rates (power) of the 2-cp-lag
model in 1000 times stochastic simulation and estimation as a
function of sample size for 2–6 sample points are displayed as
Fig. 4. The squares, circles and triangles represent successful
ﬁtting rates (power) of the 2-cp-lag model which is superior
to the 2-cp, 1-cp-lag and 1-cp models, respectively. Obviously,
the successful ﬁtting rates depend heavily on the sample size
and sampling points. The 2-cp-lag model is more easily
reduced to the 2-cp model when sample size and sampling
points become smaller, which means that the sparse sampling
weakens the ability of estimation of the absorption phase.
Assuming that 90% efﬁciency is acceptable, two sample points
cannot achieve this level even if the sample size increased from
20 to 120. It will achieve this level for three points when sample
size increased to 60 with the success rate of 93.60%. The suc-
cess rate will be 92.8% for four sampling points, when the sam-
ple size was enlarged to 50. For ﬁve and six points, 20 samples
will achieve this level with a success rate of 96.40% and
97.70% respectively. Five points might be reliable for main-
taining a high success rate for rejecting 2-cp model. If we
ignore the lag time, 40 samples for two sampling points, 30
samples for three sampling points and all from 20–120 samples
for 4–6 points are enough to estimate the model.
4. Discussion
The quality of the compartment model estimates of population
pharmacokinetic studies depends on the experimental design.
To obtain the compartment model information from designed
trials of a drug is one of the most important aspects of effective
applications of the population method. Simulation can be used
as an effective tool to assess if a design with fewer numbers of
samples per subject and smaller sample size can provide ade-
quate information to estimate the compartment model (Ette
et al., 1995). In this study, the ability of several sparse sampling
designs to provide the efﬁciency of the estimating compart-
ment model was investigated.
The pharmacokinetics of amlodipine in the healthy Chinese
volunteer population was best described by using a two-com-
partment model with an absorption lag time and ﬁrst-order
absorption and elimination. These results were conﬁrmed
Figure 2 The visual predict checks (95% prediction interval) for (a) 1cp, (b) 1cp_lag, (c) 2cp and (d) 2cp_lag model. The open circles are
the observed concentrations. The solid line represents the median observed plasma concentrations. The shadow ﬁeld of middle represents a
simulation based 95% conﬁdence interval for the median. The 2.5% and 97.5 percentiles of the observed data are presented with dashed
lines and the 95% conﬁdence intervals for the corresponding model predicted percentiles are shown as shadow ﬁelds.
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strap, and diagnostic plots. Series sparse sampling designs were
investigated by the stochastic simulation and estimation meth-
od. Our results clearly showed the efﬁcient estimation of the
compartment model under different sample sizes and sample
points. In conclusion, the two points sampling design is not
recommended. Five points are more reliable for compartment
model estimation. If it is acceptable, 20 samples are enough to
estimate the compartment model. Both 60 samples with three
points and 50 samples with four points could achieve over
90% success rate. Three points (180 blood collection points)
might be better than four points (200 blood points) and for
patients three points is more acceptable than four points. An-
other reason is that raising from three to four points does not
show as large an improvement as two points increasing to
three points. Maybe because the three points sampling is taken
from the absorption, distribution and elimination phases,respectively. It further suggested the reasonability of selecting
sampling points from different phases. The sample location in
this study is not thoroughly investigated.
D-optimization is a most widely accepted theoretical ap-
proach to investigate the optimal sampling strategy. The crite-
rion of determining optimal sampling time is maximization of
the determinant of the Fisher information matrix. However, it
should be noted that this criterion gave equal weight to all the
parameters in the Fisher information matrix, which may not
always be desirable and the success of optimization techniques
rely on accurate prior information being available (Green and
Duffull, 2003). These designs require ﬁxed sample times or
sampling windows, which may burden the patient and the
clinic in an outpatient setting (Kimko and Duffull, 2003).
Stochastic simulation is a valuable tool to investigate the
efﬁciencies of different designs before clinical trial execution.
The evaluation in this study illustrated how sample size and
Table 2 The comparison of mean and median of 1000 times bootstrap and origin pharmacokinetic parameters.
Population NONMEM 2cp-lag model estimate Bootstrap resampling
Parameters Mean (SE) 95% CI Mean Median 95% CIa
CL/F(L/h) 0.0124 (0.0028) 0.007  0.018 0.0125 0.0119 0.007  0.019
V2/F(L) 0.0589 (0.0057) 0.048  0.070 0.0595 0.0591 0.051  0.069
Q/F(L/h) 0.0205 (0.0022) 0.016  0.025 0.0205 0.0208 0.015  0.025
V3/F(L) 17.1 (6.31) 4.732  29.468 18.227 17.887 7.766  30.615
KA(1/h) 0.022 (0.00075) 0.021  0.023 0.0222 0.0221 0.021  0.023
ALAG(h) 0.46 (0.0353) 0.391  0.529 0.4612 0.4603 0.404  0.521
The variance of the interindividual random eﬀects
xCL 0.419 (0.138) 0.149  0.689 0.4840 0.4509 0.191  0.889
xV2 0.286 (0.059) 0.170  0.402 0.2890 0.2842 0.199  0.388
xQ 0.0327 (0.012) 0.009  0.056 0.0334 0.0308 0.014  0.061
xV3 0.25 (0.133) 0.0  0.511 0.2631 0.2501 0.080  0.495
xKA 0.00924 (0.003) 0.003  0.015 0.0089 0.0088 0.003  0.014
xALAG 0.118 (0.032) 0.055  0.181 0.1192 0.1152 0.073  0.180
The variance of the intraindividual random eﬀects
r1
b 0.0342 (0.0028) 0.029  0.040 0.0336 0.0335 0.029  0.038
r2
c 1.7E-3 (8.5E-4) 1.4E-5  3.6E-3 1.8E-3 1.8E-3 4.4E-04  3.3E-03






















































0 50 100 150
(a) (b)
(c) (d)
Figure 3 The observed plasma concentrations versus the population predictions (a) and individual predictions (b). The slim black solid
line is the unit line. The thick solid line is a nonparametric regression line. The scatter plot of the absolute value of the individually
weighted residuals versus individual predictions is shown in (c) and conditional weighted residuals (CWRES) versus time is plotted in (d).
68 X.-h. Huang et al.sampling points inﬂuence the compartment model estimation.
This method can be used for similar study since the variety of
this study was obtained from a real clinical trial data instead ofsetting a ﬁxed value arbitrarily. It could also be used and might
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Figure 4 The scatter plots of successful ﬁtting rates of 2-cp-lag model as a function of sample size for 2–6 sample points. The squares,
circles and triangles represent successful ﬁtting rates of 2-cp-lag model superior to 2-cp, 1-cp-lag and 1-cp models, respectively.
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The present study was conducted to use the stochastic simula-
tion and estimation method to evaluate the effects of sample
size and number of samples per individual on the model devel-
opment and evaluation. The results showed that the quantita-
tive methodology of stochastic simulation and estimation is
valuable for efﬁciently estimating compartment model and
can be used for other similar model development and evalua-
tion approaches.Acknowledgments
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